10x Genomics (TXG) Stock Forecast & Price Target

$28.34
+0.54 (+1.94%)
(As of 12:34 PM ET)

10x Genomics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 9 Analyst Ratings

Analysts' Consensus Price Target

$60.22
112.50% Upside
High Forecast$75.00
Average Forecast$60.22
Low Forecast$45.00
TypeCurrent Forecast
4/24/23 to 4/23/24
1 Month Ago
3/25/23 to 3/24/24
3 Months Ago
1/24/23 to 1/24/24
1 Year Ago
4/24/22 to 4/24/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$60.22$62.44$60.55$53.08
Predicted Upside112.50% Upside24.54% Upside21.80% Upside20.83% Upside
Get 10x Genomics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.

TXG Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TXG Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

10x Genomics Stock vs. The Competition

Type10x GenomicsMedical CompaniesS&P 500
Consensus Rating Score
2.89
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside112.87% Upside972.35% Upside10.15% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/18/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$60.00 ➝ $55.00+88.61%
4/10/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$55.00 ➝ $45.00+27.51%
2/16/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$68.00 ➝ $63.00+25.62%
12/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$60.00+17.19%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$55.00+13.08%
12/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Neutral$36.00 ➝ $54.00+12.17%
9/19/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$70.00+51.16%
8/7/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$65.00+18.20%
8/4/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$65.00 ➝ $75.00+28.23%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:52 PM ET.

TXG Price Target - Frequently Asked Questions

What is 10x Genomics's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for 10x Genomics stock is Moderate Buy based on the current 1 hold rating and 8 buy ratings for TXG. The average twelve-month price prediction for 10x Genomics is $60.22 with a high price target of $75.00 and a low price target of $45.00. Learn more on TXG's analyst rating history.

Do Wall Street analysts like 10x Genomics more than its competitors?

Analysts like 10x Genomics more than other Medical companies. The consensus rating score for 10x Genomics is 2.89 while the average consensus rating score for medical companies is 2.68. Learn more on how TXG compares to other companies.

Does 10x Genomics's stock price have much upside?

According to analysts, 10x Genomics's stock has a predicted upside of 28.32% based on their 12-month stock forecasts.

What analysts cover 10x Genomics?

10x Genomics has been rated by Barclays, Deutsche Bank Aktiengesellschaft, and Stifel Nicolaus in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:TXG) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners